F-star Biotechnologische Forschungs-und Entwicklungsges mbH added another €8 million (US$11.5 million) in a third closing of a Series A round that had previously yielded €9 million, spread across two tranches. Read More
Privately held Icon Bioscience Inc., which has flown under the radar since it was founded in 2007, wanted to wait until it had proof of its drug delivery technology for controlled-release ophthalmic products before emerging on the public scene. (BioWorld Today) Read More